Introduction
Despite advances in the surgical and therapeutic revascularization techniques, treatment of ischemic heart disease and peripheral vascular disease remains a challenge. Gene transduction for therapeutic angiogenesis is being considered as a potential alternative strategy (Abo-Auda et al., 2003; Merkle et al., 2003) . Myocardial ischemia strongly triggers the release of various angiogenic factors and chemokines (Helisch et al., 1999) . More than 20 molecules with angiogenic potential including acidic and basic fibroblast growth factors (aFGF and bFGF), angiopoietins (Ang) including Ang-1 and Ang-2, VEGF isoforms, hepatocyte growth factor (HGF), chemokines including IL-1, IL-8 and MCP-1 have been identified and assessed for their role in angiogenesis (Koblizek et al., 1998; Gonacalves et al., 2000; Jain et al., 2000; Poltorak et al., 2000; Ahmet et al., 2003) . The more welldocumented are the VEGF isoforms due to their pivotal role in angiogenesis (Lee et al., 2002) .
Angiogenesis being a cascade of sequential events needs a coordinated and concerted involvement of various types of cells under the influence of different mitogens (Carmiliet 2000) . Two commonly adopted High efficiency transduction of hum an VEGF 165 into hum an skeletal m yoblasts: in vitro studies approaches for therapeutic angiogenesis include protein therapy using direct injection of recombinant cytokines and the gene therapy approach based on the delivery of gene encoding for one or more angiogenic factors (Dazu et al 2001; Khan et al., 2003) . The later strategy has been accomplished using naked DNA injection, non-viral vectors and viral vectors into the myocardium (Rosengart et al., 1999; Kornowski et al., 2000; Kay et al., 2001; Tse et al., 2003) . A more recent diversification from these two basic strategies is to achieve angiogenesis through transplantation of cells (Chekanov et al., 2003; Nishida et al., 2003; Stamm et al., 2003) .
The feasibility of ex-vivo cell mediated gene transfer is being widely investigated (Pagel et al., 1995; Floyd et al., 1998) . More recently, genetically engineered myoblast mediated FGF2 delivery for revasularization in a model of acute skin flap ischemia has been documented (Rinch et al., 2001) . Similar reports have also been published for angiogenic gene delivery to the myocardium using myoblast (Suzuki et al., 2001; Yau et al., 2001) . We have already reported human myoblasts (HM) carrying β-galactosidase reporter gene as a model for concomitant cell transplantation and therapeutic gene delivery to the skeletal muscle as well the myocardium in the animal models (Haider et al., 2002) . The transplanted HM were found to survive and express the reporter gene up to 30 weeks after transplantation. We are reporting a highly efficient, adenoviral vector mediated hVEGF165 gene transduction into HM and their characterization for transduction and expression efficiency. We reckon that the use of HM as carriers of exogenous human angiogenic gene will be safer for future in vivo studies.
M aterials and M ethods C ell culture
Human myoblasts were manufactured according to the in-house Standard Operating Protocols (SOP) and trade secrets with a license of the U.S. Patent No. 5,130,141 (Law et al., 1992) . They were cultured in Cell Transplants Singapore Pte. Ltd., according to current Good Manufacturing Practice (cGMP) and ISO9001. At harvest, the yield was 98% pure for human myoblasts. The cells were maintained with patented Super Medium (Cell Transplantation Inc., Singapore) containing 10% FBS at 37 o C in 5% CO2 incubator until confluent and were frequently passaged after every 48-72 h. HEK-293 cells (human embryonic kidney cells line) were obtained from Dr. Ge Rouwen, Biological Sciences Lab, National University of Singapore and maintained in DMEM. Human umbilical vein endothelial cell (HUVEC) was gifted by Dr. Song Jie, Atherosclerosis Research Lab, National University of Singapore. The cells were grown in F-12K medium (ATCC). HeLa cells were a gift from Associate Prof. Hanry Yu, Department of Physiology, National University of Singapore. All the cells lines were maintained in their respective basal medium supplemented with 1% penicillin/steptomycin, 2% glutamine and 10% FBS. The cells were cultured at 37 o C in 5% CO2.
Construction and purification of adenovirus vector carrying hum an VEG F165
The recombinant adenovirus was packaged using HEK-293 cells. The adenoviral shuttle plasmid pCA14 carrying human VEGF165 (hVEGF165) driven by immediate early human cytomegalovirus promoter was rescued into the deleted E1 region of the pJM17 Ad5 genomic plasmid by co-transfection into HEK-293 cells. The virus was plaque purified thrice before amplification. Cell density of about 80-90% confluence was infected in 2% FBS supplemented DMEM. Following full cytopathic effect development, cells were harvested, repeated freeze/thaw and purified by cesium chloride gradient ultracentrifugation following standard procedures. The viral titer was estimated by endpointassay (Quantum Biotechnology) and the virus particle was calculated based on 1 optical density equivalent to 1.25×10 12 particles/ml. The recombinant virus was confirmed replication-incompetent with undetectable E1 DNA by PCR.
Adenovirus carrying human VEGF165 (Ad-hVEGF165) was propagated in HEK-293 cells, cultured at a cell density of 1×10 6 cells in 75-mm 2 tissue culture flasks using DMEM cell culture medium supplemented with 10% FBS. At 70% confluence, the cells were infected with Ad-hVEGF165 or Null-Ad (Null adenovirus). At stipulated time, the supernatant from 293 cells was removed, centrifuged to remove any cell debris and used for transduction of HM.
Im m unostaining for desm in expression
Human myoblast was cultured on poly-lysine coated microscopic glass slides. The cells were immunostained using desmin immunstaining kit as per manufacturer's instructions (Sigma). The proportion of desmin positive myoblasts was calculated from the ratio between stained and unstained cell counting the various microscopic fields.
Transduction of hum an m yoblasts w ith hVEG F 165 Human myoblasts was cultured at 1×10 7 cell density in 225-mm 2 tissue culture flasks. The cells were exposed to various virus: cell number ratios for 2 h, 4 h, 8 h, and 24 h. At pre-determined time intervals post-infection, the virus infection medium was replaced with normal super medium for 24 h. The transduction procedure was repeated three times to optimize transduction conditions.
Characterization of hVEG F165 transduced hum an m yoblasts
The detection of hVEGF165 secreted from the transduced HM was carried out using hVEGF165 Sandwich ELISA kit (Chemicon International Inc., US). The human hVEGF165 transduced human myoblasts (hVEGF165-HM) were grown in six-well tissue culture plates at a cell density of 2×10 5 cells/well, using human myobalsts transduced with null adenovirus vector (Null Ad-HM) and non-transduced myoblasts as control. The supernatant from each well was collected at regular time intervals from day 1 for up to 18 days at two days interval and kept frozen at -20 o C until used for assay. The assay was performed as per instructions of the supplier. Briefly, 100 µl samples or hVEGF165 standards were coated into each designated well in triplicate and 25 µl of diluted biotinylated rabbit anti-hVEGF165 polyclonal antibody was dispensed into each well. The plate was incubated at room temperature for 3 h, washed three times with wash buffer and incubated at room temperature for 45 min with streptavidin conjugated alkaline phosphatase. The presence of primary antibody was detected by color reagent system and absorbance was determined at 490 nm using ELISA plate reader (SLT Lab Instruments, Australia).
W estern blot analysis
The HM were grown in six well tissue culture plates and transduced with Ad-hVEGF165 or null adeno-virus as described above. Samples from each well were obtained at 48 h after transduction. Cell samples were washed three times with PBS. The cells were resuspended in 0.5 ml PBS and lysed by 5 cycles of freeze and thaw. The cell extract was centrifuged at 5,000 rpm to remove cell debris. The supernatant was used as the cell lysate for immunoblotting. The aliquots of the samples were boiled in denaturing sample buffer and separated on 10% SDS polyacrylamide gel under reducing conditions using 50 mM Tris/glycine buffer pH 8.8. The separated proteins were transferred onto nitrocellulose membrane (Sigma Chemicals) for Western blot analysis and processed for the detection of hVEGF165. The blots were washed three times with 10 mM Tris/HCl wash buffer pH 7.6 containing 0.05% Tween-20. The membrane was incubated at room temperature for one hour in 2% bovine serum albumin in wash buffer to prevent any non-specific antibody binding. The membrane was then incubated with 1:500 dilution of anti-hVEGF165 specific polyclonal antibody (Chemicon). The antibody binding was visualized with diaminobenzidine visualization system.
Endothelial cell proliferation assay HUVEC cells were cultured in F-12K medium supplemented with 10% fetal bovine serum and 20 U/ml heparin. For cell proliferation assay, 1×10 5 cells/well were cultured in six well tissue culture plates in triplicate for each sample. After 24 h culture with DMEM containing 2% FBS, the cells were washed twice with PBS and medium from Ad-VEGF165-HM, non-transduced, Null Ad-HM, simple growth medium and AdhVEGF165 medium with 1:1,000 anti-hVEGF165 antibody. The cells were grown for 72-96 h at 37 o C in 5% CO2, harvested by trypsinization using 0.1% trypan blue and counted.
[H 3 ] thym idine incorporation assay
HUVEC were cultured in F-12K medium supplemented with 10% FBS and 20 units/ml heparin. For thymidine [H 3 ] incorporation assay, 1×10 5 cell/well were seeded in 6-well tissue culture plates in triplicate for each sample. After 24 h culture with DMEM containing 2% FBS, the cells were washed twice with PBS and medium from Ad-hVEGF165-HM, non-transduced, null Ad-HM, super medium and Ad-hVEGF165-HM medium with 1:1,000 anti-hVEGF165 antibody. Each well was supplemented with 2 µCi/ml [H 3 ] thymidine (ICN Biomedical Inc.). The cells were harvested after 72-96 h and thoroughly washed with ice-cold PBS to remove unincorporated [H 3 ] thymidine. The cells were lysed using 0.5 ml of 10.25 N NaOH and centrifuged at 5,000 rpm for 10 min to remove the cell debris. The clear supernatant (400 µl) was mixed with 4 ml scintillation buffer (Ready Safe, Beckman) and radioactivity counts were measured using Beckman LT-6500 Multipurpose Scintillation Counter (USA).
Im m unohistochem ical staining
Ad-hVEGF165-HM and null Ad-HM vector were grown on poly-lysine coated glass microscopic slides for 48 h. After washing with PBS containing 0.05% Tween-20 as wash buffer, the cells were fixed with -20 o C cold methanol for 10 min. After blocking for one hour with 1% BSA in the wash buffer to avoid non-specific antibody reaction, the cells were incubated at 37 o C with 1:500 dilution of anti-VEGF165 primary antibody (Chemicon). One hour later, the cells were washed three times with wash buffer. The secondary antibody-HRP enzyme conjugate (1:200) was added for one hour at room temperature. Finally, the cells were washed three times and visualized with DAB visualization system.
Reverse transcription (RT)-PCR analysis for hVEG F 165 gene expression in transduced hum an m yoblast
Samples from pure HM, null Ad-HM, Ad-hVEGF165-HM (on days 1, 8, and 18 days) were used for RT-PCR analysis. The RT-PCR primers of hVEGF165 5' 3' (5' ATGAACTTTCTGCTGTCTTGGGTG 3') and 3' 5' (5' TCACCGCCTCGGCTTGTCACA 3') and GAPDH 5' 3' (5' GTGGAGGAGTGGGTGTCGCTG 3') and 3' 5' (5' CGGATTTGGTCGTATTGGGCG 3') were used for amplification. The Tm and annealing temperatures for VEGF165 were 68-70 o C and 64 o C and for GAPDH were 66-70 o C and 64 o C respectively. The total RNA is isolated by using total RNA Isolation Kit (Purescript). Briefly, 300 µl cell lysis solution is added into each sample for 3 min after cells are collected. The 100 µl protein-DNA precipitation solution is added to the cell lysate for 5 min and centrifuge. The supernatant was collected and mixed with 300 µl 100% isopropanol. RNA was recovered by centrifugation followed by the addition of 50 µl RNA hydration solution to rehydrate isolated RNA. The purified RNA was kept at -80 o C until use.
The RT-PCR of HM was done by using One-step RT-PCR Kit (Qiagen). Briefly, 10 master mixtures were prepared of 10 samples (five with VEGF165 primers, five with GAPDH primers). 500 ng template total RNA of each sample was added into each master mixtures. The reverse transcription was carried out at 50 o C for 30 min followed by initial PCR activation step for 15 min at 95 o C. The denaturation and annealing temperatures were 94 o C and 64 o C respectively. The reaction was carried out for a total of 30 cycles, followed by final extension at 72 o C for 10 min.
R esults
The HM culture was more than 98% pure population of the cells as assessed by desmin staining (Figure 1) . Transduction efficiency revealed a vector dose dependent relation between the viral particle number and HM (Figure 2) . Similarly, the time of exposure of HM to Ad-VEGF165 showed a direct relation with transduction efficiency (Figure 3) . However, at a longer time exposure and at a higher viral titer, the HM showed ill effects towards viral exposure. Repeated transductions of HM improved transduction efficiency. Optimum level of transduction efficiency was achieved at 1:1,000 HM: viral ratio when transduction was carried out for 8 h exposure, three times at an interval of 24 h after every transduction (Figure 2 and 3) . The cell viability was 99% by dye exclusion method using Trypan Blue staining after transduction. ELISA results revealed that the transduced HM continued to secrete hVEGF165 for up to 30 days of observation after transduction, day '0', 24 h (5±1 ng/ml), 2 days (8±2 ng/ml) reaching peak (37±3 ng/ml) of VEGF165 in the cell culture supernatant at 7 days (Figure 4) . Our results also showed that the untransduced HM or Null Ad-HM also secreted hVEGF165, however, the level of secretion was very low (300±50 pg/ml, 800± 150 pg/ml respectively). These findings have been confirmed by immunoblotting and RT-PCR results. Immunoblotting on HM culture supernatant and cell lysate, using anti-hVEGF165 showed the presence of hVEGF165 in the medium and cell lysate. This showed that hVEGF165 is actively secreted in the medium of hVEGF165-HM. Immunochemical staining of hVEGF165-HM revealed high transduction efficiency of more than 95% for hVEGF165 ( Figure 5 ). Our RT-PCR results comply with the findings of ELISA and immunoblotting. The presence of mRNA encoding for hVEGF165 as detected by VEFG165 specific primers revealed high levels of VEGF165 gene expression (Figure 6 ).
The biological activity of hVEGF165 secreted from transduced HM was assessed through HUVEC proliferation and Thymidine [H 3 ] incorporation assays. VEGF promotes endothelial cell proliferation and triggers DNA synthesis by the endothelial cells. The two control groups of un-transduced HM and Null Ad-HM showed poor rate of proliferation as compared with experimental group (Figure 7A and B) . The effect of hVEGF165 triggered proliferation of HUVEC was inhibited by hVEGF165 specific polyclonal anti-sera ( Figure  7A and B). This is further supported by the results from thymidine incorporation assay which confirmed the biological activity of the HM secreted hVEGF165 (Figure 8 ).
D iscussion
The use of HM for hVEGF165 transduction in our study plan is to establish experimental conditions for angio- Figure 4 . Expression of hVEGF165 protein from Ad-hVEGF165-HM as a function of time. The peak of secreted hVEGF165 (37±3 ng/ml) was at 7 days post transduction, declining to 19±2 ng/ml at 30 days post transduction. Untransduced HM also secreted hVEGF165 at a low level (0.3±0.05 ng/ml) as compared to the null Ad-HM (0.8±0.1 ng/ml). myogenesis using autologous HM for hVEGF165 gene delivery. Successful gene transfer with demonstration of high efficiency transfection and high level of transgene expression in diseased myocardium has been reported (Hertulla et al., 2000) .
VEGF165 gene has been transferred into the myocardium as a naked plasmid or as a part of viral vector cassette in animal models and human studies (Lopez et al., 1998; Vale et al., 2000) . Attempts have also been made for site-specific catheter based delivery of angiogenic vectors for enhanced neovascularization (Laitinen et al., 2000) . Apart from the conventional methods, implantation of genetically engineered cells is gaining popularity these days due to its promise in tissue engineering to repair damaged myocardium secondary to myocardial infarction . One of the more fascinating approaches in the field of cardiovascular gene therapy would be to achieve therapeutic angiogenesis to enhance collateral development and tissue perfusion in the ischemic area alongside cellular myocardial reconstruction to strengthen the weakened heart muscle in the scar tissue. The potential advantage of this technique is to create a reservoir of myogenic cells that would establish as a part of the myocardial tissue. These transplanted cells will provide a transient source of angiogenic factors such as VEGF following transplantation. This may help to maintain a therapeutic level of these factors for angiogenesis in combination with tissue repair.
Most of the research on angiogenesis is focused on the use of VEGF, which is a 34-36-kDa heparin binding glycoprotein having specific receptors on the endothelial cells (Ferrara, 1999) . VEGF isoforms, VEGF165 and VEGF121 are capable of efficient stimulation of angiogenesis and are being widely considered for research and clinical application (Merkle et al., 2003) . The use of HM for cardiac muscle grafting with an added intention of transgene transfer is a two pronged strategy. The transplanted myoblasts strengthens the infarcted tissue on one hand and simultaneously serve as carriers of therapeutic gene for angiogenesis. The neovascularization thus produced enhances the probability of grafted cell survival in the otherwise hostile ischemic tissue environment.
In our present study, we have successfully transduced HM using Ad-hVEFG165 vector. The transduction efficiency and the release of the expression product of the exogenous transduced gene were very high (37±3 ng/ml). The hVEGF165 secreted from the transduced cells was identified as a 42 kDa molecular weight protein as determined by immunoblotting. The results of HUVEC proliferation assay ( Figure 7A and B) and Thymidine incorporation assay (Figure 8) showed that the hVEGF165 secreted from HM was biologically active. It triggered DNA synthesis and proliferation of endothelial cells. Furthermore, the transduced HM persistently secreted VEGF165 for up to 30 days of observation with peak levels reaching at about 7 days after gene incorporation experiment (Figure 4 and 6) . These results were in harmony with some of the previously published data (Floyd et al., 1998) .
One critical aspect in ex-vivo gene delivery is the duration of transgene expression after cell transplantation. Depending upon the mode of gene transfer into myoblasts, the gene expression has been reported to persist from 5 weeks to 3 months to 7 months, for up to a year (Lee et al., 2000; Rinsch et al. 2001; Suzuki et al., 2001; Yau et al., 2001) . High transduction efficiency and transient expression are the important features of adenovirus-mediated transduction (Benihoud et al., 1999) . We hypothesized that a transient expression of the angiogenic gene would be sufficient to initiate the process of neovascularization. The adenoviral vector construct for VEGF delivery to the myoblasts during the present study was intended to have transient expression of VEGF to initiate angiogenesis. We hypothesize that a longer term ex- pression is not needed and may lead to deleterious effects.
Once the process has set in, further expression of exogenous gene is undesired and may lead to untoward pathological events (Lee et al., 2000) . In addition to this, it has been reported that direct injection of adenoviruses carrying exogenous gene may give rise to inflammatory reactions and immune response from the host defense system (Kay et al., 2001) . The cell-based delivery is a safe alternative for angiogenic gene delivery to the myocardium. As our findings suggested that autologous donor cells continued to secrete VEGF165 for 30 days, time duration long enough to initiate and set in progression the course of neovascularization (Figure 4) . As observed during the current study, transduction with Ad-VEGF165 had no bad effects on HM in the tissue culture, the cell proliferation continued unabated and cell viability post-transduction remained 99%. Hence, it was expected that these cells upon transplantation would go on to differentiate and form muscle fibers in the host myocardium for cellular cardiomyoplasty.
To conclude, we have demonstrated hVEGF165 transduction into HM for concurrent application of cell transplantation and angiogenesis. The use of autologous cells for transplantation and human angiogenic factor for neovascularization will be much more effective and less immunogenic. 
